Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05468723
Other study ID # TP-00003 Revision: 05
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 24, 2022
Est. completion date June 18, 2022

Study information

Verified date July 2022
Source Carecubes, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a human non-significant risk (NSR) clinical study designed to objectively and participatively verify that the Carecube Negative Pressure Isolation Chamber is a safe and non-hostile environment for the patients that will be contained within the chamber during normal operations.


Description:

Device Information: The Carecube Negative Pressure Isolation Chamber is a patient isolation unit (PIU) designed for the temporary isolation of patients within a hospital to prevent particulate (biological) cross-contamination between user and patient, while enclosing the contaminated patient from the external environment. Study Description: Participants will be tasked to stay within the Carecube Negative Pressure Isolation Chamber for a minimum of three consecutive time points (1 hour apart) illustrating a plateau level for all parameters, up to a maximum of 7 hours (readings will be taken at baseline and hourly thereafter). The Carecube Negative Pressure Isolation Chamber will be set up indoors, in an emergency department and hospital floor environment. We will collect data and demonstrate that the Carecube Isolation chamber is a safe and non-hostile environment for the patients that will be contained within, during normal operations. Each participant will be asked to come to a test center facility to complete and sign the informed consent and receive instruction to interact with the simulation. Subjects will be tasked to stay within the Carecube Isolation Chamber for at least 4 hours and have 3 consecutive timepoints illustrating a plateau level for all participants parameters. Environmental data will be collected by physicians and nurses. Additionally, atmospheric Oxygen, Carbon Dioxide, humidity, and room temperature will be monitored and recorded. External to the room humidity and temperatures will also be recorded. The participant will be exposed to room temperature (° Fahrenheit) and humidity (RH%), ranging from 65°- 90° Fahrenheit and 30%-60% RH. Participants will also be asked to record on a questionnaire, in order to demonstrate that the Carecube Negative Pressure Isolation chamber is a safe and non-hostile environment for the patients that will be contained during normal operations.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date June 18, 2022
Est. primary completion date June 18, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 64 Years
Eligibility Inclusion Criteria: Male, female, non-binary between the ages of 19-65 No existing medical condition that would impact the Subject from staying within the containment system for the specified time-period. Patient is not pre-dispositioned for claustrophobia Exclusion Criteria: Subjects that have a pre-existing condition of claustrophobia Subjects that have a history of hypertension Subjects with a clinical diagnosis of generalized anxiety disorder (GAD) Subjects with a clinical diagnosis of major depressive disorder (MDD) Morbidly obese patients (BMI above 40) Subjects who are Women of Child Bearing Potential (WOCBP) who either are pregnant or suspect they are pregnant

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Carecube Negative Pressure Isolation Chamber
Subjects will be tasked to stay within the Carecube Isolation Chamber for at least 4 hours and have 3 consecutive timepoints illustrating a plateau level for all participants parameters. Environmental data will be collected by physicians and nurses [which may include physicians, physician assistants, Registered Nurses, Licensed Practical Nurses, medical technicians and emergency medical technicians (EMTs)] . Additionally, atmospheric Oxygen, Carbon Dioxide, humidity, and room temperature will be monitored and recorded on an hourly basis. External to the room humidity and temperatures will also be recorded. The participant will be exposed to room temperature (° Fahrenheit) and humidity (RH%), ranging from 65°- 90° Fahrenheit and 30%-60% RH. Participants will also be asked to record on a questionnaire, in order to demonstrate that the Carecube Negative Pressure Isolation chamber is a safe and non-hostile environment for the patients that will be contained during normal operations.

Locations

Country Name City State
United States UNMC Omaha Nebraska

Sponsors (2)

Lead Sponsor Collaborator
Carecubes, Inc. University of Nebraska

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Body Temperature Subject's body temperature maintains a normal healthy value based on their entry body temperature and outside the Carecube 4 hours
Primary Blood Pressure Subject's blood pressure stays at a normal healthy level with respect to their initial baseline 4 hours
Primary Pulse Subject's pulse stays within a normal healthy level based with respect to their initial baseline 4 hours
Primary Oxygen levels Subject's Oxygen levels stays within a normal healthy level based with respect to their initial baseline 4 hours
Primary Movement Subject is able to move within the Carecube, to include activities such as sitting up, laying down, rotating, foot flexion or other body positioning within the hospital bed located within the Carecube. 4 hours
Primary Communication Subject and provider are able to clearly and effectively communicate while the Subject is positioned within the Carecube Negative Pressure Isolation Chamber. 4 hours
Primary Environmental Condition Environment does not have an elevation of temperature, Carbon Dioxide and humidity outside a normal range as compared to the external environment of the chamber. 4 hours
Secondary Comfort Subject does not become uncomfortable or claustrophobic 4 hours
Secondary Anxiety Subject does not become anxious 4 hours
See also
  Status Clinical Trial Phase
Completed NCT02763345 - The Added Value of a Mobile Application of Community Case Management on Pediatric Referral Rates in Malawi N/A
Completed NCT00550706 - Drug Utilization Prevalence in a Pediatric Care Medical Center N/A
Completed NCT01033799 - Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers N/A
Completed NCT00761462 - BAY 0 9867 Cipro Pediatric Use Study (QUIP) Phase 3
Completed NCT05088421 - A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers Phase 1
Completed NCT00828971 - A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs Phase 3
Recruiting NCT02162966 - Safety and Efficacy Study of High Dose Colistin Phase 4
Recruiting NCT00001281 - Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV
Active, not recruiting NCT02654210 - LoewenKIDS - Infections and the Development of the Immune System
Completed NCT02226263 - Severe Necrotizing Enterocolitis in Preterm Newborns <1500g Using Probiotics Phase 2
Terminated NCT00211471 - Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.). Phase 2
Active, not recruiting NCT04342702 - A Study on the Prospective Cohort Library of COVID-19 in Southeran
Completed NCT02134548 - Sensitivity Study of Diagnostic for Detection of Chagas Infection N/A
Active, not recruiting NCT01611025 - Hospital Microbial Ecology Follow the Introduction of Ertapenem and Other Newly Introduced Antibiotic Over Time N/A
Completed NCT01361997 - Isopropyl Alcohol Against Chlorhexidine - Isopropyl Alcohol as Antiseptics to Prevent Hemoculture's Contamination Phase 3
Completed NCT00638677 - Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier Phase 4
Completed NCT02434848 - A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses Phase 2/Phase 3
Completed NCT02544139 - Specificity Study of Diagnostic for Chagas Disease N/A
Completed NCT00276198 - Efficacy Trial to Examine Efficacy of Multimicronutrient Home Supplementation in Infants Phase 3
Completed NCT02111564 - A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients Phase 3